Dashboard
Manage Tickers

ALKS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

deutsche-bank-maintains-buy-on-alkermes-lowers-price-target-to-45
Deutsche Bank Maintains Buy on Alkermes, L...
11/13/2025 11:38:51

Deutsche Bank analyst David Hoang maintains Alkermes (NASDAQ:ALKS) with a Buy and lowers the price target from $55 to $45.

truist-securities-reiterates-buy-on-alkermes-maintains-50-price-target
Truist Securities Reiterates Buy on Alkerm...
11/12/2025 18:15:06

Truist Securities analyst Joon Lee reiterates Alkermes (NASDAQ:ALKS) with a Buy and maintains $50 price target.

alkermes-eyes-global-phase-3-trial-after-encouraging-data-from-sleep-disorder-study
Alkermes Eyes Global Phase 3 Trial After E...
11/12/2025 17:46:56

Alkermes' alixorexton met key goals in a phase 2 study for narcolepsy type 2, showing significant improvements in wakefulne...

alkermes-data-from-vibrance-2-phase-2-trial-of-alixorexton-in-participants-with-narcolepsy-type-2-meets-dual-primary-endpoints-demonstrates-statistically-significant-clinically-meaningful-improvements-in-wakefulness-excessive-daytime-sleepiness
Alkermes Data From Vibrance-2 Phase 2 Tria...
11/12/2025 12:33:32

Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating a...

this-alkermes-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-tuesday
This Alkermes Analyst Begins Coverage On A...
11/11/2025 13:09:35

truist-securities-initiates-coverage-on-alkermes-with-buy-rating-announces-price-target-of-50
Truist Securities Initiates Coverage On Al...
11/11/2025 11:56:32

Truist Securities analyst Joon Lee initiates coverage on Alkermes (NASDAQ:ALKS) with a Buy rating and announces Price Target...

wells-fargo-maintains-overweight-on-alkermes-lowers-price-target-to-42
Wells Fargo Maintains Overweight on Alkerm...
10/29/2025 14:16:48

Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and lowers the price target from $44...

needham-maintains-buy-on-alkermes-raises-price-target-to-44
Needham Maintains Buy on Alkermes, Raises ...
10/29/2025 09:55:29

Needham analyst Ami Fadia maintains Alkermes (NASDAQ:ALKS) with a Buy and raises the price target from $43 to $44.

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

alkermes-raises-fy2025-gaap-eps-guidance-from-103-121-to-136-147-vs-129-est-raises-fy2025-sales-guidance-from-1340b-1430b-to-1430b-1490b-vs-1423b-est
Alkermes Raises FY2025 GAAP EPS Guidance f...
10/28/2025 11:07:42

Alkermes (NASDAQ:ALKS) raises FY2025 GAAP EPS guidance from $1.03-$1.21 to $1.36-$1.47 vs $1.29 analyst estimate. Raises FY2025...

alkermes-q3-eps-049-beats-030-estimate-sales-394185m-beat-356099m-estimate
Alkermes Q3 EPS $0.49 Beats $0.30 Estimate...
10/28/2025 11:02:01

Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.30 by 65....

preview-alkermess-earnings
Preview: Alkermes's Earnings
10/27/2025 20:01:37

deal-dispatch-from-four-roses-bourbon-to-quantum-stakes-here-are-this-weeks-sector-shake-ups
Deal Dispatch: From Four Roses Bourbon To ...
10/24/2025 16:20:19

Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across va...

breaking-down-alkermes-8-analysts-share-their-views
Breaking Down Alkermes: 8 Analysts Share T...
10/23/2025 21:01:49

piper-sandler-reiterates-overweight-on-alkermes-raises-price-target-to-45
Piper Sandler Reiterates Overweight on Alk...
10/23/2025 16:26:16

Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $3...

rbc-capital-maintains-outperform-on-alkermes-raises-price-target-to-47
RBC Capital Maintains Outperform on Alkerm...
10/23/2025 13:22:37

RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $45 ...

alkermes-strikes-21-billion-avadel-deal-gains-access-to-narcolepsy-drug-lumryz
Alkermes Strikes $2.1 Billion Avadel Deal,...
10/22/2025 19:18:55

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicin...

Core News & Articles
Alkermes To Acquire Avadel Pharmaceuticals...
10/22/2025 11:14:36

9-analysts-assess-alkermes-what-you-need-to-know
9 Analysts Assess Alkermes: What You Need ...
09/26/2025 13:00:29

Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts...

this-ciena-analyst-turns-bullish-here-are-top-5-upgrades-for-friday
This Ciena Analyst Turns Bullish; Here Are...
09/26/2025 11:55:03

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION